300601 康泰生物
收盘竞价 09-19 14:57:27
资讯
新帖
简况
【机构调研记录】先锋基金调研康泰生物
证券之星 · 09-06
【机构调研记录】先锋基金调研康泰生物
康泰生物：9月3日接受机构调研，UBS、China Merchants Fund等多家机构参与
证券之星 · 09-05
康泰生物：9月3日接受机构调研，UBS、China Merchants Fund等多家机构参与
东海证券：给予康泰生物买入评级
证券之星 · 09-02
东海证券：给予康泰生物买入评级
图解康泰生物中报：第二季度单季净利润同比减63.51%
证券之星 · 08-29
图解康泰生物中报：第二季度单季净利润同比减63.51%
康泰生物最新公告：上半年净利润同比下降67.61%
证券之星 · 08-28
康泰生物最新公告：上半年净利润同比下降67.61%
康泰生物(300601.SZ)发上半年业绩，净利润1.65亿元，同比减少67.61%
智通财经 · 08-28
康泰生物(300601.SZ)发上半年业绩，净利润1.65亿元，同比减少67.61%
康泰生物（300601）8月13日主力资金净卖出821.66万元
证券之星 · 08-14
康泰生物（300601）8月13日主力资金净卖出821.66万元
康泰生物（300601）8月9日主力资金净卖出565.42万元
证券之星 · 08-12
康泰生物（300601）8月9日主力资金净卖出565.42万元
康泰生物(300601.SZ)：四价流感病毒裂解疫苗(6-35月龄人群)获药物临床试验批准通知书
智通财经 · 08-07
康泰生物(300601.SZ)：四价流感病毒裂解疫苗(6-35月龄人群)获药物临床试验批准通知书
康泰生物最新公告：四价流感病毒裂解疫苗临床试验获批
证券之星 · 08-07
康泰生物最新公告：四价流感病毒裂解疫苗临床试验获批
7月31日康泰生物涨8.42%，嘉实中证疫苗与生物技术ETF基金重仓该股
证券之星 · 07-31
7月31日康泰生物涨8.42%，嘉实中证疫苗与生物技术ETF基金重仓该股
康泰生物涨8.42%，国信证券二个月前给出“买入”评级
证券之星 · 07-31
康泰生物涨8.42%，国信证券二个月前给出“买入”评级
7月29日康泰生物发生1笔大宗交易 成交金额1180.59万元
证券之星 · 07-29
7月29日康泰生物发生1笔大宗交易 成交金额1180.59万元
细胞免疫治疗概念盘中拉升，康泰生物涨2.93%
自选股智能写手 · 07-25
细胞免疫治疗概念盘中拉升，康泰生物涨2.93%
康泰生物（300601）7月17日主力资金净卖出395.55万元
证券之星 · 07-18
康泰生物（300601）7月17日主力资金净卖出395.55万元
康泰生物最新公告：四价流感疫苗临床试验申请获受理
证券之星 · 07-15
康泰生物最新公告：四价流感疫苗临床试验申请获受理
康泰生物(300601.SZ)四价流感病毒裂解疫苗(MDCK细胞)临床试验申请获得受理
智通财经 · 07-15
康泰生物(300601.SZ)四价流感病毒裂解疫苗(MDCK细胞)临床试验申请获得受理
【康泰生物(300601.SZ)四价流感病毒裂解疫苗(MDCK细胞)临床试验申请获得受理】智通财经APP讯，康泰生物(300601.
智通财经 · 07-15
【康泰生物(300601.SZ)四价流感病毒裂解疫苗(MDCK细胞)临床试验申请获得受理】智通财经APP讯，康泰生物(300601.
康泰生物（300601）股东杜伟民质押800万股，占总股本0.72%
证券之星 · 07-05
康泰生物（300601）股东杜伟民质押800万股，占总股本0.72%
6月24日康泰生物发生1笔大宗交易 成交金额256.28万元
证券之星 · 06-24
6月24日康泰生物发生1笔大宗交易 成交金额256.28万元
加载更多
公司概况
公司名称：
深圳康泰生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2017-02-07
主营业务：
深圳康泰生物制品股份有限公司主营业务为人用疫苗的研发、生产和销售。公司的主要产品为免疫规划疫苗、非免疫规划疫苗。公司拥有专利70余项，已上市及获批紧急使用的产品10种，在研品种30余项，基本涵盖全球重磅疫苗品种，其中，公司自主研发的用于乙肝疫苗无应答特殊人群的“60µg重组乙型肝炎疫苗（酿酒酵母）”和“双载体13价肺炎球菌多糖结合疫苗”属全球首创。
发行价格：
3.29
{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":13.49,"timestamp":1726729047000,"preClose":13.08,"halted":0,"volume":9079049,"delay":0,"floatShares":881000000,"shares":1117000000,"eps":0.4622,"marketStatus":"收盘竞价","marketStatusCode":4,"change":0.41,"latestTime":"09-19 14:57:27","open":13.19,"high":13.78,"low":13.11,"amount":122000000,"amplitude":0.0512,"askPrice":13.47,"askSize":60,"bidPrice":13.47,"bidSize":60,"shortable":0,"etf":0,"ttmEps":0.4622,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1726729200000},"adr":0,"adjPreClose":13.08,"symbolType":"stock","openAndCloseTimeList":[[1726709400000,1726716600000],[1726722000000,1726729200000]],"highLimit":14.39,"lowLimit":11.77,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116916689,"pbRate":1.62,"roa":"--","roe":"1.71%","epsLYR":0.77,"committee":0.414634,"marketValue":15067000000,"floatMarketCap":11889000000,"peRate":29.1865,"changeRate":0.0313,"turnoverRate":0.0103,"status":0},"requestUrl":"/m/hq/s/300601","defaultTab":"news","newsList":[{"id":"2465310683","title":"【机构调研记录】先锋基金调研康泰生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2465310683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465310683?lang=zh_cn&edition=full","pubTime":"2024-09-06 08:01","pubTimestamp":1725580873,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月5日披露的机构调研信息，先锋基金近期对1家上市公司进行了调研，相关名单如下：1）康泰生物 个股亮点：本公司主营业务为人用疫苗的研发、生产和销售；康泰转2于2021-08-05上市；公司主营业务为人用疫苗的研发、生产和销售，目前上市的产品包括重组乙型肝炎疫苗等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090600005676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0201","BK0239"],"gpt_icon":0},{"id":"2465542098","title":"康泰生物：9月3日接受机构调研，UBS、China Merchants Fund等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2465542098","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465542098?lang=zh_cn&edition=full","pubTime":"2024-09-05 21:45","pubTimestamp":1725543921,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年9月5日康泰生物发布公告称公司于2024年9月3日接受机构调研，UBS、China Merchants Fund、Broad Peak Investment Advisers Pte Ltd、中信建投、Point72、农银人寿、申万宏源、先锋基金、翼虎投资、U Capital、TD Asset Mgmt Inc、Oddo BHF SCA、Neumann Advisory Hong Kong Limited、Harbourview Investment Pte Ltd、Grand Alliance Asset Mgmt、Goldman Sachs Asset Mgmt、Golden Nest Capital Management参与。进展冻干人用狂犬病疫苗于2024年4月实现 上市销售，截至目前该疫苗已完成26个省、自治区、直辖市的准入， 后续将积极推动该产品的销售推广。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090500036909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0239","BK0201"],"gpt_icon":0},{"id":"2464135856","title":"东海证券：给予康泰生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2464135856","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464135856?lang=zh_cn&edition=full","pubTime":"2024-09-02 23:26","pubTimestamp":1725290783,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏,伍可心近期对康泰生物进行研究并发布了研究报告《公司简评报告：业绩短期承压，批签发量快速增长》，本报告对康泰生物给出买入评级，当前股价为13.93元。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为33.42。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090200034191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","161027"],"gpt_icon":0},{"id":"2463349782","title":"图解康泰生物中报：第二季度单季净利润同比减63.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463349782","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463349782?lang=zh_cn&edition=full","pubTime":"2024-08-29 01:56","pubTimestamp":1724867779,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物2024年中报显示，公司主营收入12.02亿元，同比下降30.54%；归母净利润1.65亿元，同比下降67.61%；扣非净利润1.22亿元，同比下降71.66%；其中2024年第二季度，公司单季度主营收入7.5亿元，同比下降23.6%；单季度归母净利润1.11亿元，同比下降63.51%；单季度扣非净利润1.07亿元，同比下降55.26%；负债率34.0%，投资收益48.17万元，财务费用1155.24万元，毛利率83.78%。财报数据概要请见下图: 以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082900002393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"gpt_icon":0},{"id":"2462460000","title":"康泰生物最新公告：上半年净利润同比下降67.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462460000","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462460000?lang=zh_cn&edition=full","pubTime":"2024-08-28 23:29","pubTimestamp":1724858991,"startTime":"0","endTime":"0","summary":"康泰生物发布2024年半年度报告，报告期内，公司实现营业收入12.02亿元，同比下降30.54%；归属于上市公司股东的净利润为1.65亿元，同比下降67.61%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082800045126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"gpt_icon":0},{"id":"2462953460","title":"康泰生物(300601.SZ)发上半年业绩，净利润1.65亿元，同比减少67.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462953460","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462953460?lang=zh_cn&edition=full","pubTime":"2024-08-28 23:20","pubTimestamp":1724858427,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)发布2024年半年度报告，营业收入12.02亿元，同比减少30.54%。归属于上市公司股东的净利润1.65亿元，同比减少67.61%。归属于上市公司股东的扣除非经常性损益的净利润1.22亿元，同比减少71.66%。基本每股收益0.15元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1174164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300601"],"gpt_icon":0},{"id":"2459169208","title":"康泰生物（300601）8月13日主力资金净卖出821.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459169208","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459169208?lang=zh_cn&edition=full","pubTime":"2024-08-14 09:24","pubTimestamp":1723598650,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月13日收盘，康泰生物报收于15.38元，下跌1.98%，换手率1.13%，成交量9.98万手，成交额1.53亿元。近5日资金流向一览见下表：康泰生物融资融券信息显示，融资方面，当日融资买入1417.96万元，融资偿还1080.57万元，融资净买入337.39万元。康泰生物主营业务：人用疫苗的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081400016545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0239","BK0046"],"gpt_icon":0},{"id":"2458648094","title":"康泰生物（300601）8月9日主力资金净卖出565.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458648094","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458648094?lang=zh_cn&edition=full","pubTime":"2024-08-12 09:23","pubTimestamp":1723425790,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月9日收盘，康泰生物报收于15.3元，下跌2.8%，换手率0.96%，成交量8.44万手，成交额1.31亿元。近5日资金流向一览见下表：康泰生物融资融券信息显示，融资方面，当日融资买入1531.28万元，融资偿还1389.61万元，融资净买入141.66万元。康泰生物主营业务：人用疫苗的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081200002652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0046","BK0239"],"gpt_icon":0},{"id":"2457143398","title":"康泰生物(300601.SZ)：四价流感病毒裂解疫苗(6-35月龄人群)获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2457143398","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457143398?lang=zh_cn&edition=full","pubTime":"2024-08-07 19:22","pubTimestamp":1723029744,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)公告，公司研发的四价流感病毒裂解疫苗(6-35月龄人群)近日获得国家药品监督管理局出具的《药物临床试验批准通知书》，根据《中华人民共和国药品管理法》《中华人民共和国疫苗管理法》及有关规定，经审查，本品符合药品注册的有关要求，同意本品进行临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1161217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK0046","BK1576","BK0239","300601","BK0201","159646","03347","BK1583"],"gpt_icon":0},{"id":"2457110028","title":"康泰生物最新公告：四价流感病毒裂解疫苗临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2457110028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457110028?lang=zh_cn&edition=full","pubTime":"2024-08-07 19:10","pubTimestamp":1723029030,"startTime":"0","endTime":"0","summary":"康泰生物公告，公司研发的四价流感病毒裂解疫苗（6—35月龄人群）近日获得国家药监局出具的《药物临床试验批准通知书》。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080700039200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK1583","BK1141","159646","BK1576","300601","03347","BK0201"],"gpt_icon":0},{"id":"2455064699","title":"7月31日康泰生物涨8.42%，嘉实中证疫苗与生物技术ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2455064699","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455064699?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:48","pubTimestamp":1722415721,"startTime":"0","endTime":"0","summary":"证券之星消息，7月31日康泰生物涨8.42%，收盘报15.96元，换手率2.18%，成交量19.23万手，成交额2.98亿元。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为嘉实中证疫苗与生物技术ETF。嘉实中证疫苗与生物技术ETF目前规模为2.99亿元，最新净值0.5456，较上一交易日下跌0.02%，近一年下跌35.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","BK0239","159646","300601"],"gpt_icon":0},{"id":"2455906290","title":"康泰生物涨8.42%，国信证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2455906290","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455906290?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:48","pubTimestamp":1722415712,"startTime":"0","endTime":"0","summary":"今日康泰生物涨8.42%，收盘报15.96元。2024年5月6日，国信证券研究员张佳博,陈益凌,马千里发布了对康泰生物的研报《常规疫苗销售收入同比增长19%，人二倍体狂犬病疫苗商业化推进中》，该研报对康泰生物给出“买入”评级。此外，东海证券研究员杜永宏,伍可心，天风证券研究员杨松近期也对该股发布了研报，同样给出“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","002736"],"gpt_icon":0},{"id":"2455122635","title":"7月29日康泰生物发生1笔大宗交易 成交金额1180.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2455122635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455122635?lang=zh_cn&edition=full","pubTime":"2024-07-29 16:31","pubTimestamp":1722241893,"startTime":"0","endTime":"0","summary":"证券之星消息，7月29日康泰生物发生大宗交易，交易数据如下：大宗交易成交价格14.75元，成交80.04万股，成交金额1180.59万元，买方营业部为中信证券股份有限公司上海分公司，卖方营业部为华泰证券股份有限公司泰州分公司。近三个月该股共发生11笔大宗交易，合计成交4.88万手。截至2024年7月29日收盘，康泰生物报收于14.75元，下跌1.6%，换手率0.61%，成交量5.33万手，成交额7896.91万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072900023236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300601","BK0201","BK0046"],"gpt_icon":0},{"id":"2454896721","title":"细胞免疫治疗概念盘中拉升，康泰生物涨2.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2454896721","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454896721?lang=zh_cn&edition=full","pubTime":"2024-07-25 10:57","pubTimestamp":1721876227,"startTime":"0","endTime":"0","summary":"07月25日，细胞免疫治疗概念盘中拉升，截至10点57分，细胞免疫治疗概念整体指数上涨1.11%，报616.970点。从个股上来看，该概念的成分股中，康泰生物涨2.93%，海欣股份、药明康德、*ST龙津涨幅居前。从资金上来看，截止发稿，细胞免疫治疗概念主力净流入为2179.25万，其中药明康德受到资金热捧，主力净流入3750.16万；拉长时间线来看，该板块近20日主力资金净流入-30.48亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072510570796820268&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072510570796820268&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0201","BK0239","300601","02359","LU0456842615.SGD","LU1997245094.SGD","603259","LU1997245177.USD","BK0046","BK0216"],"gpt_icon":0},{"id":"2452486531","title":"康泰生物（300601）7月17日主力资金净卖出395.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452486531","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452486531?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:15","pubTimestamp":1721265312,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月17日收盘，康泰生物报收于15.48元，上涨1.91%，换手率1.1%，成交量9.68万手，成交额1.5亿元。近5日资金流向一览见下表：康泰生物融资融券信息显示，融资方面，当日融资买入869.35万元，融资偿还1498.42万元，融资净偿还629.07万元。康泰生物主营业务：人用疫苗的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800014196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","300601","BK0239"],"gpt_icon":0},{"id":"2451646192","title":"康泰生物最新公告：四价流感疫苗临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2451646192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451646192?lang=zh_cn&edition=full","pubTime":"2024-07-15 19:49","pubTimestamp":1721044193,"startTime":"0","endTime":"0","summary":"康泰生物公告，公司和兰州百灵生物技术有限公司研发的四价流感病毒裂解疫苗(MDCK细胞)临床试验申请已获国家药品监督管理局受理。该疫苗适用于3周岁及以上人群，用于预防流感病毒引起的流行性感冒。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500027193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","300601","BK1583","BK0239","BK0201","BK1141","03347","BK0046"],"gpt_icon":0},{"id":"2451664681","title":"康泰生物(300601.SZ)四价流感病毒裂解疫苗(MDCK细胞)临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2451664681","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451664681?lang=zh_cn&edition=full","pubTime":"2024-07-15 19:41","pubTimestamp":1721043672,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)公告，公司今日收到国家药品监督管理局签发的受理通知书，同意受理公司和兰州百灵生物技术有限公司研发的四价流感病毒裂解疫苗(MDCK细胞)的临床试验申请。本次申请临床试验获得受理的四价流感病毒裂解疫苗(MDCK细胞)适用于3周岁及以上人群，可刺激机体产生抗流感病毒的免疫力，用于预防疫苗相关型别的流感病毒引起的流行性感冒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK0046","BK0201","03347","300601","159646","BK1583","BK1576","BK0239"],"gpt_icon":0},{"id":"2451646849","title":"【康泰生物(300601.SZ)四价流感病毒裂解疫苗(MDCK细胞)临床试验申请获得受理】智通财经APP讯，康泰生物(300601.","url":"https://stock-news.laohu8.com/highlight/detail?id=2451646849","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451646849?lang=zh_cn&edition=full","pubTime":"2024-07-15 19:41","pubTimestamp":1721043672,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0046","BK1576","300601","159646","BK1583","BK0201","BK1141","03347","BK0239"],"gpt_icon":0},{"id":"2449260387","title":"康泰生物（300601）股东杜伟民质押800万股，占总股本0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449260387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449260387?lang=zh_cn&edition=full","pubTime":"2024-07-05 21:28","pubTimestamp":1720186084,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物7月5日公开信息显示，股东杜伟民向国金证券股份有限公司合计质押800.0万股，占总股本0.72%。质押详情见下表：截止本公告日，股东杜伟民已累计质押股份3599.8万股，占其持股总数的12.64%。康泰生物主营业务：人用疫苗的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500048048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","BK0239","300601"],"gpt_icon":0},{"id":"2445301028","title":"6月24日康泰生物发生1笔大宗交易 成交金额256.28万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445301028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445301028?lang=zh_cn&edition=full","pubTime":"2024-06-24 16:52","pubTimestamp":1719219137,"startTime":"0","endTime":"0","summary":"证券之星消息，6月24日康泰生物发生大宗交易，交易数据如下：大宗交易成交价格15.82元，成交16.2万股，成交金额256.28万元，买方营业部为中信证券股份有限公司上海分公司，卖方营业部为中国国际金融股份有限公司深圳分公司。近三个月该股共发生10笔大宗交易，合计成交4.08万手。该股近期无解禁股上市。截至2024年6月24日收盘，康泰生物报收于15.82元，下跌2.77%，换手率1.0%，成交量8.85万手，成交额1.41亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400022330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0046","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦101","stockEarnings":[{"period":"1week","weight":-0.0404},{"period":"1month","weight":-0.1239},{"period":"3month","weight":-0.1946},{"period":"6month","weight":-0.4165},{"period":"1year","weight":-0.5385},{"period":"ytd","weight":-0.5126}],"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","perCapita":"13457股","boardName":"医药制造业","registeredCapital":"111691万元","compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":-0.061},{"period":"3month","weight":-0.0959},{"period":"6month","weight":-0.1085},{"period":"1year","weight":-0.1305},{"period":"ytd","weight":-0.0866}],"survey":" 深圳康泰生物制品股份有限公司主营业务为人用疫苗的研发、生产和销售。公司的主要产品为免疫规划疫苗、非免疫规划疫苗。公司拥有专利70余项，已上市及获批紧急使用的产品10种，在研品种30余项，基本涵盖全球重磅疫苗品种，其中，公司自主研发的用于乙肝疫苗无应答特殊人群的“60µg重组乙型肝炎疫苗（酿酒酵母）”和“双载体13价肺炎球菌多糖结合疫苗”属全球首创。","serverTime":1726729049532,"listedPrice":3.29,"stockholders":"65489人(较上一季度减少0.86%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}